AstraZeneca

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

AstraZeneca abandons plan for £450m vaccine plant in UK

In a shock move, AstraZeneca has ditched its plan to invest £450m in a new vaccine manufacturing plant in the UK.

News

Enhertu gets first okay for HER2-ultralow breast cancer

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

News

AstraZeneca reveals $570m investment in Canada

AstraZeneca has announced another major investment in Canada, tapping into the country's emergence as a "global hub" for clinical trials.

News

AZ, Daiichi get FDA nod for Dato-DXd in breast cancer

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.

News

Microscope view of nodular mantle cell lymphoma

AZ's Calquence gets first-line OK in mantle cell lymphoma

AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.

Boost to Enhertu's prospects as FDA clears Roche diagnostic

AstraZeneca abandons plan for £450m vaccine plant in UK

Enhertu gets first okay for HER2-ultralow breast cancer

AstraZeneca reveals $570m investment in Canada

AZ, Daiichi get FDA nod for Dato-DXd in breast cancer

AZ's Calquence gets first-line OK in mantle cell lymphoma

Sanofi gives up on amlitelimab in atopic dermatitis

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks